Form 4: Equillium Chairman Daniel Bradbury Receives Stock Options
Director Compensation Disclosure
Equillium, Inc. Chairman Daniel Bradbury was granted 70,000 stock options as part of his director compensation package.
Summary
- Chairman Daniel Bradbury received a grant of 70,000 stock options for Equillium, Inc. (EQ) common stock.
- The options have an exercise price of $2.84 per share.
- The grant date for these options is May 28, 2026.
- The options are set to expire on May 27, 2036.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which is neutral in terms of immediate market impact.
Positives
- Alignment of interests between the Chairman and shareholders through equity-based compensation.
- Standard vesting schedule ensures long-term commitment to the company.
Negatives
- The issuance of new options results in potential future dilution for existing shareholders.
Risks
- Market volatility affecting the value of the granted options.
- Potential for future dilution of equity if options are exercised.
Future Outlook
The options vest in twelve equal monthly installments starting May 28, 2026, with full vesting guaranteed by the date of the next annual meeting of stockholders.
Management Comments
- The filing confirms the grant of 70,000 options to Chairman Daniel Bradbury as part of his director compensation.
Industry Context
StockSavvy.ai notes that equity grants for directors are standard practice in the biotechnology sector to incentivize leadership and align long-term strategic goals with shareholder value.
Comparison to Industry Standards
- The use of monthly vesting schedules is consistent with standard corporate governance practices for board members in small-cap biotech firms.
- The 10-year expiration term is a standard industry benchmark for executive and director stock option plans.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Power of Attorney | Daniel Bradbury appointed Bruce D. Steel and Christine Zedelmayer as attorneys-in-fact for SEC filings. | 2026-05-31 | Administrative change to streamline regulatory compliance. |
Stakeholder Impact
- Shareholders may experience minor dilution upon the eventual exercise of these options.
Next Steps
- Vesting of options in monthly installments.
- Potential exercise of options by the reporting person in the future.
Key Dates
| Date | Description |
|---|---|
| 2026-05-28 | Grant date of stock options and date of earliest transaction. |
| 2026-05-29 | Date of filing of the Form 4. |
| 2026-05-31 | Execution date of the Limited Power of Attorney. |
| 2036-05-27 | Expiration date of the granted stock options. |
Keywords
Equillium, EQ, Form 4, Insider Trading, Stock Options, Daniel Bradbury, Biotech
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.